-

LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 2025

LONDON--(BUSINESS WIRE)--LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE).

LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE).

Share

Poster Presentation Details

Title

Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity

Date and time

Wednesday, December 10, 2025, 08:00 (GMT)

Poster number

309P

Location

The Churchill Room, Queen Elizabeth II Centre, London

Bispecific TCE Overview

For the selected target, LabGenius has developed a selectivity-enhanced TCE. The company’s lead optimisation platform, EVA™, was used to discover and concomitantly optimise a TCE with improved killing selectivity, potency, efficacy, and manufacturability. The biological mechanism underlying this enhanced selectivity is based on the principle of avidity. By harnessing avidity-driven selectivity, the optimised TCE can distinguish between healthy and diseased cells based on differential tumour-associated antigen expression.

About LabGenius Therapeutics

LabGenius Therapeutics is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVA™, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. LabGenius Therapeutics operates a hybrid business model that includes partnering with biotech and pharmaceutical companies in parallel with pursuing a wholly-owned therapeutic pipeline. For more information, please visit www.labgeniustx.com, or connect on LinkedIn.

Contacts

Media: press@labgeni.us
Corporate / business development: partnerships@labgeni.us

Industry:

LabGenius Therapeutics

Release Versions
EnglishSpanish (Summary)GermanFrenchItalian (Summary)Dutch (Summary)
Hashtags
#AI
#drugdiscovery
#machinelearning
#proteinengineering

Contacts

Media: press@labgeni.us
Corporate / business development: partnerships@labgeni.us

Social Media Profiles
LabGenius Therapeutics on LinkedIn
LabGenius
More News From LabGenius Therapeutics

LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody

LONDON--(BUSINESS WIRE)--LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together, the compa...

LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes

LONDON--(BUSINESS WIRE)--LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic antibodies, today announced a second collaboration with Sanofi. This collaboration combines LabGenius’ AI/ML-driven antibody design capabilities with Sanofi’s expertise in the development of therapeutic NANOBODY® molecules to co-optimise proteins for therapeutically valuable properties. Following the success...

LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors

LONDON--(BUSINESS WIRE)--LabGenius, a pioneer in the use of machine learning (ML) for antibody discovery, today announced that accomplished scientific leaders Hendrik-Tobias Arkenau, MD/PhD/FRCP, and Victor Greiff, PhD, will join their world-class team of advisors. As distinguished experts in academia and biotech, they will play an important role in advancing LabGenius’ antibody discovery platform and its ability to discover next-generation oncology treatments. “The calibre of these appointment...
Back to Newsroom